We are excited to announce that Cellestial Health has successfully raised $515,000 in our latest funding round, marking an important milestone in our journey to transform brain health therapies. As a pioneering University of Cambridge spin-off, our company is challenging the conventional approach to neurological disorders by shifting the focus towards the often-overlooked networks of brain cells known as astrocytes. Traditionally, approved drugs have predominantly safeguarded only one half of the brain, leaving the rest vulnerable to the relentless progression of diseases such as Parkinson’s. At Cellestial Health, we believe that the whole brain deserves protection, which is why we are dedicated to developing best-in-class, safe small molecule therapeutics aimed at halting, and potentially reversing, the progression of debilitating brain disorders.
The fresh infusion of capital will be instrumental in advancing our research and development efforts, fueling the next phase of our innovative drug development pipeline. These funds will support critical preclinical studies and help us refine our lead compounds, as well as facilitate early collaborations and strategic partnerships with academic institutions and clinical researchers. Our team, driven by the vision of providing comprehensive brain protection, is poised to leverage this investment to accelerate our mission toward a future where more effective treatments are accessible to those affected by Parkinson’s and other neurodegenerative conditions.
This achievement not only underscores the market’s confidence in our novel approach but also reinforces our commitment to addressing an unmet need in neurological medicine. We extend our heartfelt thanks to our investors and partners for their trust and support as we continue to pave the way for the next generation of brain health therapeutics.
